Although five TKIs targeting EGFR mutations (afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib) are approved in Japan, none are recommended in the Japan Lung Cancer Society clinical practice guidelines for the treatment of patients with EGFR exon 20 insertion mutations [13]. This evidence concerns the gene EGFR and lung cancer.